Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma

Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma
The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2007 by National Cancer Institute (NCI).   Recruitment status was  Recruiting

First Received on July 19, 2006.  
Last Updated on December 7, 2011  
History of Changes
Sponsor: Duke Cancer Institute
Collaborator: National Cancer Institute (NCI)
Information provided by: National Cancer Institute (NCI) Identifier: NCT00354068

RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving imatinib mesylate together with temozolomide may kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of imatinib mesylate when given together with temozolomide in treating patients with malignant glioma.

Condition Intervention Phase
Brain and Central Nervous System Tumors Drug: imatinib mesylate
Drug: temozolomide
Other: pharmacological study
Phase 1

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: A Phase I Study of Imatinib Mesylate in Combination With Temozolomide in Patients With Malignant Glioma

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:

  • Maximum tolerated dose [ Designated as safety issue: Yes ]
  • Dose-limiting toxicity [ Designated as safety issue: Yes ]
  • Safety and tolerability [ Designated as safety issue: Yes ]
  • Pharmacokinetics [ Designated as safety issue: No ]
  • Anti-tumor activity [ Designated as safety issue: No ]

Estimated Enrollment: 40
Study Start Date: July 2004

Detailed Description:


  • Determine the maximum tolerated dose and dose-limiting toxicity, if attainable, of imatinib mesylate in combination with temozolomide in patients with malignant glioma.
  • Characterize the safety and tolerability of imatinib mesylate, including acute and chronic toxicities, in these patients.
  • Determine the effect of temozolomide on the pharmacokinetics (PK) of imatinib mesylate at each dose level.
  • Evaluate the impact of enzyme-inducing anti-epileptic drug (EIAED) coadministration on the PK of imatinib mesylate using a population-based PK approach.
  • Evaluate the antitumor activity of imatinib mesylate plus temozolomide.

OUTLINE: This is a dose-escalation study of imatinib mesylate. Patients are stratified according to concurrent enzyme-inducing anticonvulsants (e.g., phenytoin, phenobarbital, carbamazepine, fosphenytoin, primidone, oxcarbazepine) (yes vs no).

Patients receive oral imatinib mesylate once or twice daily on days 1-8 and oral temozolomide once daily on days 4-8. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Cohorts of patients receive escalating doses of imatinib mesylate until the maximum tolerated dose is determined.

On days 1 and 8 of course 1, blood is drawn for pharmacokinetic studies.

PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Histologically confirmed malignant glioma

    • Any of the following subtypes:

      • Glioblastoma multiforme
      • Gliosarcoma
      • Anaplastic astrocytoma
      • Anaplastic oligodendroglioma
      • Anaplastic oligoastrocytoma
    • Previous histologic diagnosis of a lower grade of glioma allowed if there is histologic evidence of progression to a diagnosis of malignant glioma
    • Multifocal disease allowed
  • Must have undergone prior conventional external-beam radiation therapy
  • Stable disease, disease recurrence, or relapsed disease

    • Must not have received any systemic therapy for this recurrence or relapse
    • No prior progressive disease
  • No central/systemic fluid collections (pericardial effusion, pulmonary effusion, ascites) ≥ grade 2
  • No evidence of intratumor hemorrhage on pretreatment diagnostic imaging, except for stable post-operative grade 1 hemorrhage


  • Karnofsky performance status 70-100%
  • Absolute neutrophil count > 1,500/mm³
  • Hemoglobin > 9 g/dL
  • Platelet count > 100,000/mm³
  • AST and ALT < 2.5 times upper limit of normal (ULN)
  • Bilirubin < 1.5 times ULN
  • Creatinine < 1.5 times ULN
  • No chronic renal disease
  • No active uncontrolled infection
  • No uncontrolled diabetes
  • No excessive risk of bleeding, as defined by occurrence of any of the following:

    • Stroke within the past 6 months
    • History of CNS or intraocular bleed
    • Septic endocarditis
  • No history of labile hypertension
  • No congestive heart failure
  • No poorly controlled hypertension
  • No myocardial infarction within the past 6 months
  • No history of poor compliance with antihypertensive regimen
  • No other severe and/or uncontrolled medical disease that would preclude study participation
  • No peripheral edema ≥ grade 2
  • No gastrointestinal bleeding
  • No gross hematuria
  • No other active systemic bleeding
  • Patients must not have experienced toxicity ≥ grade 3 with prior treatment with either temozolomide or imatinib mesylate
  • No other primary malignancy within the past 5 years except basal cell skin cancer or carcinoma in situ of the cervix or other cancer not currently clinically significant nor requiring active interventions


  • See Disease Characteristics
  • Recovered from all prior therapy
  • Prior surgical resection(s) allowed
  • At least 2 weeks since prior surgery
  • At least 2 weeks since prior chemotherapy (6 weeks for nitrosoureas)
  • At least 2 weeks since prior external-beam radiotherapy
  • At least 2 weeks since prior investigational drugs
  • More than 1 week since prior biologic, immunotherapeutic, or cytostatic agents
  • No concurrent warfarin
  Contacts and Locations

Please refer to this study by its identifier: NCT00354068

United States, North Carolina
Duke Cancer Institute Recruiting
Durham, North Carolina, United States, 27710
Contact: Clinical Trials Office – Duke Cancer Institute     888-275-3853        
Sponsors and Collaborators
Duke Cancer Institute
Study Chair: David A. Reardon, MD Duke Cancer Institute
  More Information

Additional Information:

Publications: Identifier: NCT00354068    
History of Changes
Other Study ID Numbers: CDR0000483760, DUMC-5514-06-1R2, NOVARTIS-DUMC-5514-06-1R2
Study First Received: July 19, 2006
Last Updated: December 7, 2011
Health Authority: Unspecified

Keywords provided by National Cancer Institute (NCI):

adult anaplastic oligodendroglioma
adult giant cell glioblastoma
adult gliosarcoma
adult mixed glioma
adult anaplastic astrocytoma
recurrent adult brain tumor
adult glioblastoma

Additional relevant MeSH terms:

Nervous System Neoplasms
Central Nervous System Neoplasms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms by Site
Nervous System Diseases
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antineoplastic Agents
Therapeutic Uses
Protein Kinase Inhibitors
Enzyme Inhibitors processed this record on August 21, 2012

Leave a Reply

You can use these HTML tags

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>




5 × one =